UBP-1213

N/A

Report date: 2025/01/15 15:45:15

Base Information

Drug NameUBP-1213
Drug Alias Name重组人源化抗BLyS单克隆抗体注射液UBP-1213UBP 1213sc
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionB-cell-activating factor/B lymphocyte stimulator inhibitors
TargetsB-cell-activating factor/B lymphocyte stimulator
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Huaxin Kangyuan Biomedicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Junshi Biosciences Co LtdWuhan Huaxin Kangyuan Biomedicine Co Ltd
Inactive CompaniesSuzhou Union Biopharm Biosciences Co LtdShanghai Zhonghe Medicine Technology Co Ltd
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A